Tag Archives: CBIO

A Director at Catalyst Biosciences (NASDAQ: CBIO) is Buying Shares

Yesterday, a Director at Catalyst Biosciences (CBIO – Research Report), John Richard, bought shares of CBIO for $9,950. Following this transaction John Richard’s holding in the company was increased by 205.59% to a total of $13.64K. In addition to John

The President & CEO of Catalyst Biosciences (NASDAQ: CBIO) is Buying Shares

Yesterday, the President & CEO of Catalyst Biosciences (CBIO – Research Report), USMAN NASSIM, bought shares of CBIO for $15.64K. This recent transaction increases USMAN NASSIM’s holding in the company by 24.05% to a total of $75.73K. In addition to

JonesTrading Keeps a Buy Rating on Catalyst Biosciences (CBIO)

JonesTrading analyst Matthew Cross reiterated a Buy rating on Catalyst Biosciences (CBIO – Research Report) today and set a price target of $30.00. The company’s shares closed last Monday at $8.23. According to TipRanks.com, Cross is a 4-star analyst with

Oppenheimer Maintains a Buy Rating on Catalyst Biosciences (CBIO)

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Catalyst Biosciences (CBIO – Research Report), with a price target of $24.00. The company’s shares closed last Monday at $7.52. According to TipRanks.com, DeGeeter is a

Oppenheimer Reaffirms Their Buy Rating on Catalyst Biosciences (CBIO)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Catalyst Biosciences (CBIO – Research Report) today and set a price target of $24.00. The company’s shares closed last Monday at $7.51. According to TipRanks.com, DeGeeter is a 4-star analyst with

Chardan Capital Sticks to Their Buy Rating for Catalyst Biosciences (CBIO)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Catalyst Biosciences (CBIO – Research Report), with a price target of $25.00. The company’s shares closed last Monday at $4.77, close to its 52-week low